series-a
Stage
2020
Founded
2
Investors
About
Akamis Bio is a clinical-stage oncology company developing Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics to treat solid tumors, primarily focusing on colorectal cancer by using intravenously delivered viral vectors to activate the patient's immune system against tumor cells.
Explore Akamis Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.